Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give written consent to participate.
- People aged between 18 and 80 years old, of any gender.
- People whose general physical functioning is rated as fully active or restricted only in strenuous activity (as measured by a standard medical scoring system called the ECOG scale, rated 0 or 1).
- People whose doctors expect them to survive for at least 12 weeks.
- People whose prostate cancer has been confirmed by laboratory testing of tissue or cell samples to be a type called adenocarcinoma.
- People whose cancer has continued to grow or spread after receiving taxane chemotherapy and at least one previous hormonal therapy treatment.
Who may not be able to join:
- People who have previously been treated with a type of drug called an androgen receptor (AR) degrader.
- People who are planning to receive any other cancer treatment during the course of this trial.
- People who have received another experimental drug or unapproved treatment within the 4 weeks before starting this trial.
- People who are known to have cancer that has spread to the brain.
- People who have a serious medical condition, such as an infection that is not under control, significant abnormal laboratory results, or a psychiatric illness.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +0518-81220121
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Maximum tolerated dose (MTD); Recommended Phase 2 Dose (RP2D) of HRS-5041
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.